障害者政策総合研究事業（精神障害分野）
（○：委員長）
| 鹿島 晴雄 | 慶應義塾大学医学部 客員教授 | ||
| 精神医学 | |||
| 鹿島晴雄,加藤元一郎,本田哲三： 認知リハビリテーション. 医学書院,東京,1999.10. |
|||
| Kashima H, Faloon Ian, Mizuno M, Asai M(eds.) Comprehensive Treatment of Schizophrenia. Springer, Tokyo, 2002.1. |
|||
| 鹿島晴雄,古城慶子,古茶大樹,針間博彦,前田貴記 編著: 妄想の臨床. 新興医学出版社,東京, 2013.6. |
|||
| 川上 憲人 | 東京大学大学院医学系研究科 特任教授／一般財団法人淳風会 代表理事理事長 | ||
| 精神保健学 | |||
| Kawakami N, Sasaki N, Asaoka H, Kuroda R, Tsuno K, Imamura K. Effects of workplace measures against COVID-19 and employees' worry about them on the onset of major depressive episodes: A 13-month prospective study of full-time employees. J Affect Disord. 2023 Feb 1;322:187-193. | |||
| Imamura K, Tran TTT, Nguyen HT, Sasaki N, Kuribayashi K, Sakuraya A, Bui TM, Nguyen AQ, Nguyen QT, Nguyen NT, Nguyen KT, Nguyen GTH, Tran XTN, Truong TQ, Zhang MW, Minas H, Sekiya Y, Watanabe K, Tsutsumi A, Kawakami N. Effect of smartphone-based stress management programs on depression and anxiety of hospital nurses in Vietnam: a three-arm randomized controlled trial. Sci Rep. 2021 May 31;11(1):11353. | |||
| Kessler RC, Kazdin AE, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Altwaijri YA, Andrade LH, Benjet C, Bharat C, Borges G, Bruffaerts R, Bunting B, de Almeida JMC, Cardoso G, Chiu WT, Cía A, Ciutan M, Degenhardt L, de Girolamo G, de Jonge P, de Vries YA, Florescu S, Gureje O, Haro JM, Harris MG, Hu C, Karam AN, Karam EG, Karam G, Kawakami N, Kiejna A, Kovess-Masfety V, Lee S, Makanjuola V, McGrath JJ, Medina-Mora ME, Moskalewicz J, Navarro-Mateu F, Nierenberg AA, Nishi D, Ojagbemi A, Oladeji BD, O'Neill S, Posada-Villa J, Puac-Polanco V, Rapsey C, Ruscio AM, Sampson NA, Scott KM, Slade T, Stagnaro JC, Stein DJ, Tachimori H, Ten Have M, Torres Y, Viana MC, Vigo DV, Williams DR, Wojtyniak B, Xavier M, Zarkov Z, Ziobrowski HN; WHO World Mental Health Survey collaborators. Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. World Psychiatry. 2022 Jun;21(2):272-286. | |||
| ○ | 中込 和幸 | 国立精神・神経医療研究センター 理事長 | |
| 精神神経学・臨床精神神経薬理 | |||
| Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull, 45(2): 350-359, 2019. | |||
| Nakagome K, Yokoi Y, Nakagawa A, Tani M, Nishioka G, Yoshimura N, Furukawa TA, Watanabe K, Mimura M, Iwanami A, Abe T. Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. J Affect Disord. 282: 1011-1020, 2021. | |||
| Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 8(3): 191-201, 2021. | |||
| 夏苅 郁子 | やきつべの径診療所 医師 | ||
| 精神医学 | |||
| Natsukari I.，Higuchi M.，Tsujimoto T.：How do patients and families evaluate attitude of psychiatrists in Japan?: quantitative content analysis of open-ended items of patient responses from a large-scale questionnaire survey．BMC Psychiatry，23；253，2023 |
|||
| 「精神科担当医の診察態度」を患者・家族はどのように評価しているか―約6,000人の調査結果とそれに基づく提言― 夏苅 郁子, 夏苅 直己, 金原 明子, 熊倉 陽介, 笠井 清登, 福田 正人, 池淵 恵美．精神経誌. 120 (10): 868-886, 2018 |
|||
| 当事者・家族からみた精神医学研究の倫理―症例報告における本人同意を中心に―. 夏苅 郁子．精神経誌. 121 (11): 858-864, 2019 | |||
| 樋口 進 | 独立行政法人国立病院機構久里浜医療センター 院長 | ||
| 精神医学 | |||
| Higuchi S, Matsushita S, Imazeki H, Kinoshita T, Takagi S, Kono H: Aldehyde dehydrogenase genotypes in Japanese alcoholics. Lancet 343: 741-742, 1994. | |||
| Higuchi S, Matsushita S, Murayama M, Takagi S, Hayashida M: Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am J Psychiatry 152: 1219-1221, 1995. | |||
| Higuchi S, the Japanese Acamprosate Study Group: Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry 76(2):181-8, 2015. | |||
| 水野 雅文 | 都立松沢病院 院長 | ||
| 臨床精神医学 | |||
| Clinical practice and research activities for early psychiatric intervention at Japanese centers. Mizuno M, Suzuki M, Matsumoto K, Murakami M, Takeshi K, Miyakoshi T, Ito F, Yamazawa R, Kobayashi H, Nemoto T, Kurachi M. Early Interv Psychia 3: 5-9, 2009 | |||
| Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. Ito S, Nemoto T, Tsujino N, Ohmuro N, Matsumoto K, Matsuoka H, Tanaka K, Nishiyama S, Suzuki M, Kinoshita H, Ozawa H, Fujita H, Shimodera S, Kishimoto T, Matsumoto K, Hasegawa T, Mizuno M. European Psychiatry 30; 995-1001, 2015 | |||
| Long-term course of cognitive function in chronically hospitalized patients with schizophrenia transitioning to community-based living. Nemoto T, Niimura H, Ryu Y, Sakuma K, Mizuno M. Schizophrenia Res 155; 90-95, 2014 | |||
| 吉村玲児 | 産業医科大学医学部精神医学 教授 | ||
| 産業精神医学、脳画像研究、分子精神薬理 | |||
| Watanabe C, Konno Y, Hino A, Nagata M, Muramatsu K, Tateishi S, Tsuji M, Ogami A, Yoshimura R, Fujino Y; CORoNaWork project. Relationship between alcohol consumption and telecommuting preference-practice mismatch during the COVID-19 pandemic. J Occup Health. 2022 Jan;64(1):e12331 | |||
| Tesen H, Watanabe K, Okamoto N, Ikenouchi A, Igata R, Konishi Y, Kakeda S, Yoshimura R. Volume of Amygdala Subregions and Clinical Manifestations in Patients With First-Episode, Drug-Naïve Major Depression. Front Hum Neurosci. 2022 Jan 3;15:780884. | |||
| Fujii R, Watanabe K, Okamoto N, Natsuyama T, Tesen H, Igata R, Konishi Y, Ikenouchi A, Kakeda S, Yoshimura R. Hippocampal Volume and Plasma Brain-Derived Neurotrophic Factor Levels in Patients With Depression and Healthy Controls. Front Mol Neurosci. 2022 May 6;15:857293. | |||
